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Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control 
viral replication. However, natural virological suppression and absence of immune dysfunction are 
not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain 
the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, 
diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence 
of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was 
performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels 
of total HIV-1 DNA (<20 copies/106 CD4+ t-cells) without evidence of replication-competent viruses 
(<0.025 IUPM), consistent with high levels of defective genomes, strong cellular HIV-1-specific immune 
response, and a high poly-functionality index (>0.50). Inflammation levels of EEC were similar to HIV-1 
negative donors. Remarkably, they showed an exceptional lack of viral evolution and 8-fold lower 
genetic diversity (<0.01 s/n) in env gene than other EC. We postulate that these EEC represent cases of 
spontaneous functional HIV-1 cure. A non-functional and non-genetically evolving viral reservoir along 
with an HIV-1-specific immune response seems to be key for the spontaneous functional cure.
The use of combination antiretroviral therapy (ART) results in sustained undetectable plasma viremia in HIV-
1-infected individuals. The success of ART led to initial optimism that HIV-1 may be cured by ART alone; how-
ever subsequent studies indicating that such a cure may take as long as 70 years1,2 led researchers to attempt 
complementary strategies to reduce viral persistence and potentially facilitate HIV-1 remission3. However, this 
has proven extremely difficult to achieve because it entails the eradication of any infectious viral form from the 
body. This has only putatively been achieved so far in two individuals, the Berlin and London patients4,5. A less 
stringent objective, known as functional cure, consists in the permanent suppression of HIV-1 viral replication in 
the absence of ART even if full viral eradication is not achieved6.
1Virología Molecular, Laboratorio de Referencia e Investigación en Retrovirus, Centro Nacional de Microbiología, 
Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. 2AIDS Research Institute IrsiCaixa, Badalona, Spain. 
3Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. 4Clinical Unit of Infectious Diseases, Microbiology 
and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, 
University of Seville, Seville, Spain. 5Centro Sanitario Sandoval, Hospital Clínico San Carlos. IdISSC, Madrid, 
Spain. 6AIDS Immunopathology Unit. Laboratorio de Referencia e Investigación en Retrovirus. Centro Nacional 
de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. 7Division of Infectious Diseases, 
Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60011, USA. 8University of Vic-Central 
University of Catalonia (UVic-UCC), Vic, Spain. 9Catalan Institution for Research and Advanced Studies (ICREA), 
Barcelona, Spain. 10These authors contributed equally: Ezequiel Ruiz-Mateos, María Salgado, Javier Martinez-Picado 
and Cecilio Lopez-Galindez. *email: jmpicado@irsicaixa.es; clopez@isciii.es
open
2Scientific RepoRtS |         (2020) 10:1902  | https://doi.org/10.1038/s41598-020-58696-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Elite controllers (EC) represent a small proportion of HIV-infected patients with a spontaneous control of 
HIV replication at undetectable levels. However, they are heterogeneous in terms of long-term clinical, virolog-
ical and immunological progression. Among them, there is a subgroup of subjects who have an asymptomatic 
HIV-1 infection and prolonged control of clinical progression without ART. The closest cases of spontaneous 
functional HIV-1 cure are potentially represented by this clinical phenotype of slow or no disease progression7. 
The underlying mechanisms contributing to this control include host and viral factors8,9. Our previous work stab-
lished differences in EC with long-term non-progression compared to EC that ultimately lost control10. Previous 
reports have described several selected cases of durable control over HIV-1 replication without ART11,12; however, 
the cases described herein are Exceptional Elite Controllers (EEC) with no disease progression for more than 25 
years. The question whether these individuals can be considered cured remains unresolved. Also, there is a need 
for differential markers that can characterize these unique cases of potential HIV-1 remission.
In this study, we characterized three EEC diagnosed for 25, 28 and 29 years with an extensive follow-up, 
permanent control of viral replication, and no sign of disease progression. We investigated these individuals to 
determine if they can be considered spontaneous cases of HIV-1 functional cure. Multiple host genetic, immu-
nological, and virological factors were examined to distinguish this extraordinary phenotype and to identify 
potential diagnostic markers.
Materials and Methods
individuals, samples and clinical characteristics. The study individuals were selected from a previ-
ous long-term EC cohort9. These subjects have been followed in the Centro Sanitario Sandoval (a primary sex-
ual clinic without antiretroviral prescription belonging to the Hospital Clínico San Carlos. IdISSC, Madrid) for 
more than 20 years. All individuals were diagnosed with a second-generation ELISA (Abbot) and confirmed by 
Western-Blot (BioRad) after 5 to 6 years of the estimated infection. Participants gave informed consent for molec-
ular and genetic studies. In March 2017, 500 mL of peripheral blood was drawn to perform a comprehensive 
analysis of multiple immunological and virological markers. All clinical investigations were conducted accord-
ing to the principles expressed in the Declaration of Helsinki. The study was approved by the Research Ethics 
and Animal Welfare Committee of the Instituto de Salud Carlos III (CEI PI 05_2010-v3) and by the Ethics and 
Clinical Research Committee of the Hospital Clínico San Carlos in Madrid (Number C.I. 16/490-E).
Viral persistence. Total proviral HIV-1 DNA. Total proviral reservoir was quantified in two samples, the 
2017 and another 11 to 13 years before. Purified peripheral CD4+ T cell-lysed (Miltenyi Biotec, Germany) extracts 
were used for total HIV-1 DNA by droplet-digital polymerase chain reaction (ddPCR)13. To circumvent sequence 
mismatches in viral sequences, two primer sets in the viral 5′ long terminal repeat (5-LTR) and gag regions were 
employed. The RPP30 housekeeping gene was quantified to normalize sample input. We analyzed 1.5–1.8 million 
cells in several replicates, with a limit of detection of (LOD) 1–3 copies/106 CD4+ T cells. Raw ddPCR data were 
examined using the QX100™.
Quantitative Viral Outgrowth Assay (qVOA). The replication-competent reservoir was measured on fresh 
CD4+ T cells from each HIV-1 individual in 28–63 × 106 CD4+ T cells in a limiting dilution cell culture assay13. 
Supernatants from day 14 were quantified with p24Gag ELISA (Perkin-Elmer, USA). Infectious HIV-1 units per 
million (IUPM) CD4+ T cells were determined using IUPMStats v.1 (https://silicianolab.johnshopkins.edu/) 
based on the maximum likelihood method.
Plasma viral load and residual viremia. Viral load was determined with the Quantiplex HIV-1 RNA 2.0, 3.0 and 
the Versant NA (Siemens, Germany) with different limits of detection. For residual viremia determination, nine 
mL of plasma were ultracentrifuged at 170,000 g at 4 °C for 30 minutes before HIV-1 RNA quantification using the 
Abbott Real-Time HIV-1 assay (Abbott, Ill, USA)4,14 with a LOD of 0.5 copies/mL.
Cell-Associated HIV-1 RNA. Viral transcription was evaluated by quantification of cell-associated HIV-1 RNA 
in purified CD4+ T cells by a one-step reverse-transcription ddPCR (Bio-Rad, USA) with primers and probe in 
the viral 5-LTR and gag gene, and in the housekeeping gene of TATA-binding protein (TBP)13. Samples were 
analyzed on several replicates with 3–5 million cells for each subject. Raw ddPCR data were analyzed using the 
QX100™ Droplet Reader and the QuantaSoft v.1.6 software (Bio-Rad, USA) with a variable LOD between 0.03 
and 0.05 (ratio HIV/TBP).
Genetic studies. Nucleotide sequence and phylogenetic analysis in env gene. Sequences were obtained by 
limiting dilution in a 614 bp C2–V5 fragment in env gene15. All sequences with gaps and hypermutation (only 
two in one sample from EEC-3) were excluded of analysis. Near full-length genome analysis was performed with 
overlapping limiting dilution PCR16. Viral dating of the individual sequences was carried out according to17. 
Co-receptor usage was predicted with WebPSSM tool (https://indra.mullins.microbiol.washington.edu/
webpssm/) using the SINSI scores.
All nucleotide sequences generated in this study were submitted to GenBank under accession numbers: 
AY501160–AY501179, AY501254–AY501269, KC595083–KC595089, KC595099–KC595105, KC595118–
KC595119, EU644051, EU644056–EU644060, MH595843, MH595844, MH595846, MN068093–MN068211 
and MN055643.
Quasispecies diversity analysis. We selected sequences from individual quasispecies in the HIV-1 database 
(http://hiv.lanl.gov/) from the same region analyzed in the study. We included infected individuals with undetect-
able viral load under prolonged ART (range [2–15 years])18,19, long-term viremic non progressors (LTNPs) with 
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more than 10 years of infection and transient EC10 defined as individuals that lost spontaneous viral control dur-
ing the follow-up, for comparison with the study subjects. We estimated the average diversity over sequence pairs 
for each time point in every individual and calculated the average number of base differences per site (p-distance) 
with 500 bootstrap replicates using MEGA6. All positions containing gaps and missing data were eliminated. 
Differences in the average p-distance per individual between groups were tested for significance using pairwise 
Wilcoxon Rank-Sum Test in R v3.5.0, applying the Benjamini-Hochberg procedure for multiple comparisons 
correction (cut off for significance False Discovery Rate 0.05).
immune responses. Cell stimulation. Peripheral blood mononuclear cells (PBMCs) were thawed, washed 
and in vitro stimulated with overlapped HIV-1 (Gag)-specific peptide pool (NIH AIDS Research and Referenced 
Reagent Program) as described10,20.
Immunophenotyping and intracellular cytokine staining. Stimulated PBMCs were stained with sur-
face and intracellular marker antibodies (Supplementary Information Fig. 1)21. For dendritic cell immu-
nostaining, myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) were defined as 
Lin2-HLA-DR + CD11c + CD123- and Lin2-HLA-DR + CD11c-CD123 + , respectively21. PBMCs were analyzed 
in a LSR Fortessa Cell Analyzer (BD Biosciences, Spain).
Susceptibility and viral inhibition assay. CD4+ T cells alone or in combination with autologous CD8+ 
T cells from each patient were infected by spinoculation with 40 ng of p24Gag of the laboratory viral strain HIV-
1NFN-SX (CCR5 tropic), and HIV-1NL4–3 (CXCR4 tropic). CD4+ T cells were activated for 3 days with PHA and IL-2 
before infection. Supernatants were sampled at day 7 and quantified with HIV-1 p24Gag ELISA (Perkin-Elmer life 
Sciences, USA).
Assay of soluble biomarkers. Plasma samples were collected in EDTA-lined tubes, and aliquoted and 
stored at −20 °C. The levels of high sensitivity C-reactive protein (hsCRP) and β2-microglobulin (β2M), D-dimer, 
IL-6 and sCD163 were performed as described22.
HIV-1 antibody determination. Plasma antibody responses were measured in two samples, the 2017 one 
and another 14 to 19 years before for comparison with two long term viremic controllers as controls (#12 and 
#60) with a follow-up of >10 years with > 500 cells/µl and VL >2,000 cp/µl. End-point plasma titers of HIV-1 
antibodies were measured in an enzyme immunoassay (Genscreen™ HIV-1/2 Version 2, Bio-Rad). Antibodies 
against the HIV-1 proteins were determined by Western Blot (Biokit, Werfen, Spain) and Line Immuno Assay 
(InnoLia, Fujirebio Europe N.V, Belgium) and quantified with the LiRAS software. Neutralizing HIV-1 antibody 
titers in purified IgGs were tested against a mini panel of isolates23.
Statistical analysis. Changes over time in total HIV-1 DNA were evaluated using the Wilcoxon signed rank 
test. Gag-specific T-cell response poly-functionality was quantified with the poly-functionality index algorithm24 
employing 0.1.2 beta version of the “FunkyCells Boolean Dataminer” software (www.FunkyCells.com) provided 
by Dr. Martin Larson (INSERM U1135, France). Analyses were performed with Prism 7 (GraphPad, USA) and 
the statistical significance was set at 5% for all tests.
Results
clinical characteristics of the individuals. The three individuals of the study (EEC-3, EEC-9, and EEC-
56) maintained undetectable viral loads (except two early blips in EEC-9) and stable CD4+ and CD8+ T-cell 
counts in absence of ART for more than 25 years of infection (Table 1 and Fig. 1A–C). Hepatitis C Virus (HCV) 
infection was diagnosed in the three individuals because of intravenous drug use (IVDU) and all reported viral 
clearance, either spontaneously or after treatment (Table 1). The individuals reported no further exposure to 
HIV-1 since their diagnosis. The two females of the study gave birth uninfected children in absence of any ART. 
All individuals were classified as clinical status A, with no symptoms of HIV-1 clinical progression or AIDS 
defining events.
Participants showed several host protective haplotypes, including HLA-B*57:01, HLA-B*58:01, HLA-B*27:05 
or HLA-B*14:029,25. In addition, all individuals presented the T > C mutation in the HLA-C polymorphism 
(rs9264942) in homozygosis (Table 1) associated with lower plasma viremia and increased levels of HLA-C 
expression25. All subjects displayed three to four host protective haplotypes and a high genetic score (Table 1)9,25.
Viral persistence. To evaluate the extent of viral persistence in the study subjects we used the most sensitive 
assays available, and compared with values obtained from samples from individuals on ART26. The quantification 
of HIV-1 DNA in infected CD4+ T cells, which are believed to constitute most of the latent reservoir in peripheral 
blood, showed detectable, albeit extremely low (median of 10.4 [9.1–23.0] copies/106 CD4+ T cells) total HIV-1 
DNA in all subjects (Fig. 1D). Similar numbers of provirus-containing cells were detected in frozen samples 
obtained 11 to 13 years earlier (median of 12.5 [IQR 2.5–31.3] copies/106 CD4+ T cells) (data not shown) suggest-
ing the stability of the viral reservoir for long periods of time.
As total HIV-1 DNA indistinctly measures both defective and replication-competent forms, we quantified 
the frequency of IUPM in CD4+ T cells in a co-cultured quantitative viral outgrowth assay (qVOA). We did not 
detect any replication competent virus in a large amount (28–63 million cells) of highly activated CD4+ T cells 
from the individuals, indicating values of IUPM below 0.025 (Fig. 1E).
The ultrasensitive plasma viremia assay only detected 2 copies of HIV-1 RNA per mL of plasma in EEC-9 and 
in the other two subjects it was undetectable in 9 ml of plasma (Fig. 1F). Quantification of cell-associated HIV-1 
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RNA (ca-HIV-1 RNA) showed absence of viral transcription in peripheral CD4+ T cells in the three subjects in 
more than 1 million tested cells (Fig. 1G).
Sequence analysis, genetic variability and evolutionary dynamics of viral populations. HIV-1 
viral replication is inevitably linked with viral diversity and evolution27. Therefore, we retrospectively explored 
genetic evolution in HIV-1 DNA samples from the study subjects during the last 15 years. A total of 86 env 
sequences from seven different time points over 14 years were obtained from EEC-3, and 94 env sequences from 
nine different time points over 19 years were recovered from EEC-56. Only two env sequences from one out of 
five time points were obtained from EEC-9 over 15 years. All env sequences corresponded to R5-tropic viruses 
according to PSSM genotypic test. Of all the 182 recovered sequences, only two from one sample in EEC-3 were 
hypermutated, compared to greater numbers found in other HIV-1-infected subjects or individuals on ART28,29 
which support the very low viral replication level in these EEC.
We inferred the HIV-1 infection time of the individuals based on the correlation between Spanish env 
sequence divergence and sampling time17, generating estimations from 1983 to 1986 (Table 1). These estimations 
suggest that primary infections occurred five to six years before diagnosis and thus these subjects may have been 
infected for more than 30 years.
In addition, we intended to obtain near full-length genome sequences from proviral DNA. After 337 ampli-
fication attempts with 12.4 × 106 CD4+ cells and 6.4 × 106 PBMCs, only 11 were positive, 9 from patient EEC-3 
and 1 for each of EEC-9 and EEC-56. Of these 11 positives, only one complete genome was recovered in EEC-3 
(GeneBank MN055643). This sequence showed a G > A deleterious mutation in the major splice donor site in 
position 290 that suppose a very limited replicative capacity of the virus30,31. The remaining sequences (92%) 
showed important deletions throughout the genome mostly in pol to env genes. These data supported the notion 
that most provirus in these individuals were defective. Altogether, these results show that this group of EEC has 
very limited levels of viral persistence in blood, with an extremely low HIV-1 DNA reservoir in peripheral CD4+ 
T cells with no capacity to generate viral mRNA, viral particles or replication competent virions.
The phylogenetic trees showed very short branches with the major presence of viral sequences with no dis-
tance to the most common recent ancestor (Fig. 2A). This pattern was already evident in the first sample and 
it was maintained in different samples over the years. There were isolated small clusters of sequences showing 
longer branches in EEC-3 and EEC-56, which were not hypermutated. However, these viral populations were 
evolutionary dead ends and did not appear in further samples.
Moreover, the genetic variability of the viral quasispecies showed a very restricted genetic diversity, estimated 
to be around 0.010 ± 0.003 substitutions per nucleotide (s/n) throughout the entire follow-up (Fig. 2B). The 
degree of env-based heterogeneity was up to eight times lower in EEC than in other HIV-1-infected groups with 
controlled viral replication, including subjects on ART, viremic LTNP or transient EC one year before the loss of 
control (FDR < 0.05) (Fig. 2B). Altogether, the practically null viral genetic evolution and extremely low complex-
ity of the viral populations support the absence of viral replication in our EEC group over 30 years.
evolution of immune responses. HIV-1-specific T-cell responses and poly-functionality. The magnitude 
of Gag-specific T-cell response was calculated as the percentage of Gag-specific CD8+ T-cells producing at least 
EEC-3 EEC-9 EEC-56
Year of birth 1956 1957 1957
Sex Male Female Female
Race Caucasian Caucasian Caucasian
Estimated year of infectionª 1983 ± 2 1986 ± 2 1984 ± 2
Year of HIV-1 diagnosis 1988 1992 1989
Age at diagnosis 32 35 32
Transmission routeb IVDU IVDU IVDU
Remarks — HIV-1 negative child HIV-1 negative child
HCV coinfection 1996 1992 1993
Treatment RBV/IFNα (2008) Spontaneous clearance DAA (2017)
Genetic markers
   CCR5 ∆32 rs333c 11 11 11
   CCR2 V64I rs1799864c 11 11 11
   HLA C rs9264942 c 22 22 22
   HLA A 02:01, 02:05 02:01, 31:01 01:01, 02:01
   HLA B 27:05, 58:01 39:01, 57:01 14:02, 57:01
   Genetic Score 4 3 4
Table 1. Clinical, epidemiological and host-genetic characteristics. aViral dating performed in the last sample 
and estimated according to17. bNo further expositions after HIV-1 diagnosis. c“1” indicates the most frequent 
allele and “2” the mutant. IVDU, intravenous drug user; RBV, ribavirin; IFNα, interferon α, DAA, direct acting 
antivirals.
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one intracellular cytokine (TNFα, IL-2 and/or IFNγ). EEC presented higher levels of Gag-specific total CD8+ 
T-cells when compared with HIV-1-infected individuals on suppressive ART (Fig. 3A). Such differences were 
also detected in Central Memory (CM), Effector Memory (EM) and Terminally Differentiated (TD) CD8+ T-cell 
levels (Supplementary Information. Figure 2A,C). Simultaneous release of multiple cytokines was determined 
using the poly-functionality index (pINDEX). The pINDEX in Gag-specific total CD8+ T-cells in EEC was higher 
in three-, four- and five-functions (p = 0.017, p = 0.022, and p = 0.008 respectively) when compared with subjects 
on suppressive ART (Fig. 3B and Supplementary Information. Figure 2D,E). These values were clearly higher than 
those of previously published with transient EC one year before the loss of control10.
CD4+ susceptibility and CD8+ viral inhibition. To analyze the susceptibility of the target cells to HIV-1 infection, 
we pulsed autologous CD4+ T cells from each individual with laboratory-adapted R5- and X4-tropic viral strains 
for 7 days (Fig. 3C,D). This assay shows that CD4+ T cells from the individuals were susceptible to HIV-1 infec-
tion. When we added autologous CD8+ T cells to these co-cultures, we observed a reduction of viral replication 
from 11 to 74% with the X4-tropic virus and up to 63% with the R5 tropic virus (Fig. 3C,D). Thus, host CD4+ T 
cells are not intrinsically refractory to HIV-1 infection with R5 or X4-tropic viruses, and that host CD8+ T cells 
are effective in suppressing viral replication ex vivo.
Myeloid cell quantification. We also compared innate immune cellular subsets from EEC with HIV-1-infected 
individuals on ART and with non-HIV-1-infected healthy donors (HD) who were matched with EEC by sex 
and age. EEC had increased levels of total peripheral mDCs compared with subjects on ART (Fig. 3E), while no 
statistical differences were observed comparing EEC with HD. Similar results were obtained comparing the levels 
of myeloid subsets CD1c+ and CD141+ (Suppl. Figure 2F,G). No differences were observed in pDCs (data not 
shown). Thus, EEC showed more preserved levels of CD1c+ and CD141+cells than subjects on ART, and similar 
levels than sex/age-matched HD and other EC32.
Inflammation biomarkers. EEC had lower levels of hsCRP, β2-microglobulin and D-dimer levels than subjects 
on ART, but comparable to HD (Fig. 4A–E). IL-6 and sCD163 were similar between EEC and ART groups, despite 
the levels of IL-6 and sCD163 were higher than in HD, probably due to previous history of HCV and residual 
expression of HIV antigens.
Figure 1. Clinical characteristics and HIV-1 reservoir quantification. (A–C) Plasma RNA viral load, absolute 
CD4+ and CD4+ T cell percentage over time in the individuals studied. Grey symbols for viral load indicate 
values below the detection limit. (D–G) Viral reservoir measurements of (D) total HIV-1 DNA, (E) Infectious 
Units per million cells (IUPM) in a qVOA assay, (F) ultrasensitive plasma viral load and (G) cell associated RNA 
(caHIV-1-RNA). Open symbols indicate undetectable values. Light grey bands are the interquartile range from 
standard HIV-1-infected individuals under treatment26.
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Figure 2. Genetic variability and evolutionary dynamics of viral populations (A) Phylogenetic trees with env 
gene sequences of the individuals during follow-up. The evolutionary history was inferred in trees by using 
the Maximum Likelihood method based on the General Time Reversible model. The percentage of trees in 
which the associated taxa clustered together with values over 70% is shown next to the branches. Initial tree for 
the heuristic search was obtained by applying the Neighbor-Joining method to a matrix of pairwise distances 
estimated using the Maximum Composite Likelihood approach. A discrete Gamma distribution was used to 
model evolutionary rate differences among sites (4 categories). The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site. Evolutionary analyses were conducted in MEGA6. Different 
colors were used to indicate the sampling time. (B) Genetic variability analysis of samples from different groups 
of HIV-1 individuals with a controlled infection (see Materials and Methods).
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HIV-1-specific antibody levels. All EEC included in this study had detectable antibodies against all viral pro-
teins in the LIA-scan analysis and western blot analysis. However, HIV-1-specific antibody levels, determined 
by ELISA over 14 to 19 years of follow-up, were consistently lower (p = 0.0040) than in viremic LTNP controls 
(Fig. 4F). Participants displayed a low, albeit persistent, neutralizing response against a mini panel of isolates (data 
not shown).
Discussion
Herein we characterize three exceptional elite controllers who spontaneously controlled HIV-1 replication and its 
associated clinical pathogenesis for more than 25 years. According to our observations, the almost total absence 
of viral diversity and evolution analyzed during at least 15 years, probably due to a replication-impaired viral res-
ervoir, adds to previously described protective host genetic factors and effective immune responses.
All three EEC individuals included in this study showed a consistently low viral DNA reservoir in peripheral 
CD4+ T cells that was 50 times lower than in individuals on ART using the most sensitive techniques26. Total 
HIV DNA, cell-associated HIV RNA, residual plasma viremia, and IUPM were also lower than other values inde-
pendently reported for EC33,34. Moreover, HIV-1 env sequences had nearly null viral genetic evolution, extremely 
low complex populations and ancestral dating supporting the absence of viral replication over three decades. 
This replication impairment is further supported by the variation in only two nucleotides between the only com-
plete genomic sequence of EEC-3 and another one obtained 12 years earlier15. The lack of sequence heterogene-
ity despite a long-term untreated infection might reflect a combination of a slow-evolving virus and the clonal 
expansion of infected immune cells35 as suggested by the presence of identical viral clusters in the phylogenetic 
trees. Finally, the low levels of proviral DNA seemed to be largely defective (>92%), since they had no capacity to 
generate viral mRNA, viral particles or replication competent virions, implying limited viral persistence in these 
EECs. The lack of viral replication, as shown by different markers (Fig. 1D–G) and low hypermutation, despite 
detectable HIV-1 DNA has been mainly associated with the presence of proviral defective genomes and the sta-
bility of the viral reservoir15,16,36.
Low population size and viral diversity are associated with low replication and viral fitness37. These viral char-
acteristics favour important fitness losses, because of the irreversible accumulation of deleterious mutations, 
known as the Muller´s ratchet effect as observed “in vitro”38. The combination of these factors is able to prevent 
viral fitness recovery, and even if some remaining virus is present in the body, it will not generate replication com-
petent viruses because viral populations do not have enough variability to recover fitness39. The low diversity and 
Figure 3. Cellular Immune responses. (A) Total CD8+ T-cell Gag-specific response from EEC and HIV-
1-infected individuals on suppressive ART. (B) INDEX of polyfuncionality (pINDEX) of Gag-specific total 
CD8+ T-cells from EEC and HIV-1-infected individuals on suppressive ART based on the proportions of cells 
producing intracellular combinations of IFN-γ, TNF-α, IL-2. (C,D) Viral inhibition assay. Assay of the ex vivo 
ability of CD8+ T cells to inhibit superinfected autologous CD4+ T cells of the three individuals. The figure 
shows day 7 of an infection with a laboratory viral strain (C) HIV-1NFN-NX (CRR5-tropic) and (D) HIV-1NL4–3 
(CXCR4-tropic). Percentage of inhibition of CD4+ vs CD4+:CD8+ T cells is indicated in each individual. (E) 
Total myeloid dendritic cell quantification, comparing EEC with HIV-1-infected individuals on ART and non-
HIV-1-infected healthy donors (HD). (A,B and E) Differences between groups were determined by Mann-
Whitney U test.
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population size could have contributed to the maintenance of the control of viral replication in the participants 
during the follow-up. All study subjects showed the lowest viral diversity values among comparative groups of 
subjects on ART or LTNP with viral load control. In addition, in a previous study we showed that low diversity 
and lack of viral evolution was highly correlated with permanent viral control in persistent EC10. On the contrary, 
transient EC who lost control during the follow-up showed higher levels of genetic diversity10 (Fig. 2B). Thus, 
extremely low viral diverstiy could be a convenient prognostic marker for the identification of these EEC.
The functional characterization of viruses from EEC has been limited by the impossibility of complete virus 
recovery. In a previous study, EEC-56 showed the major presence of 228 nucleotide deletions in the 5′ LTR–gag 
region; in EEC-3 a 247 nucleotide deletion was positioned in pol gene up to the vif orf15. These deleted genomes 
became dominant during follow-up15. In other studies, we could clone env sequences from EEC-3 in recombinant 
viruses that displayed a very limited and retarded replication capacity40,41, similarly to what has been observed in 
env recombinant viruses from some EC42. Pseudoviruses with env clones from EEC-3 exhibited a very low CD4 
binding, transfer and fusion capacity, and a very inefficient cell signaling resulting in a very restricted replicative 
capacity41.
According to the data reported in this work, viral antigens and/or truncated viral proteins could be generated 
in these individuals from defective genomes or from new alternative spliced HIV-RNA variants with transla-
tionally competent ORFs as reported in cART subjects43. The apparent limited amount of peripheral viral anti-
gen might be associated with the observed low, albeit detectable, levels of HIV-1-specific antibodies, including 
neutralizing antibodies (data not shown). However, such levels were still superior to those of the two long-term 
described cases of HIV-1 cure after allogeneic stem cell transplant with a CCRΔ32 donor4,5. Likewise, both fre-
quency and poly-functionality of Gag-specific CD8+ T-cell responses were higher in EEC when compared with 
subjects on ART (Fig. 3A) and similar or above the median of a group of persistent EC (with more than 18 years 
of controlled infection) and higher than those of transient EC10. The CTL responses supported the capacity of the 
immune system to mount effective adaptive immune responses as confirmed by the ex vivo viral inhibition assay. 
Inhitibion from autologous CD8+ T cells was similar to previous described EC and higher than comparisions 
with non-HIV infected donors44. Innate immune responses seem to be relatively normalized as for the quantifi-
cation of inflammation biomarkers and frequency of myeloid cells when compared to HD individuals. Only IL-6 
and sCD163 were slightly superior compared to HD to subjects on ART. Values shown in Fig. 4A–E were in the 
range of those found in indepentdent cohorts of EC32,45. This could be due to the previous long-term story of HCV 
infection, and in fact, sCD163 has been proposed as a marker of liver fibrosis46. This is a substantial difference 
with previously published EC profiles where despite the viral control, inflamation levels were maintained over 
Figure 4. Inflammation biomarkers and antibody titers. (A–E) Different inflammatory markers were analyzed 
including (A) hsCPR, (B) β2-microglobulin, (C) D-dimer, (D) IL-6 and (E) sCD163. EEC individuals were 
compared with HIV-1-infected individuals on ART and non-HIV-1-infected healthy donors (HD). (F) Plasma 
antibody titers, expressed as the inverse of the final serum dilution with a positive signal, in two samples 14 to 
19 years apart.
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time10,47. Whether this could be a distinctive marker easy to assay for EEC needs to be examined in extended 
populations, but previous works with persistent EC suggested this idea10,48. The interplay of T cells with the 
preserved number and functions of innate cells might have been a critical factor for the maintenance of the high 
HIV-1-specific T-cell responses in these subjects49. Although there is sligth decline in CD4 + T-cell levels in EEC-
9, this decrease can be considered physiological with aging, during the 20 years of follow up and with the fact 
that the studied subjects are now over 60 years old, and moreover this diminution is comparable with European 
uninfected individuals50.
We can only speculate how these HIV-1-infected subjects have resulted in this EEC phenotype of potential 
functional viral suppression. Thus, primary infection might have occurred with a low fitness viral founder strain, 
or alternatively, initial innate immune responses might have shaped the selection of an unfit virus. Host genetic 
factors, including those related with the HLA function, and cellular-adaptive immune responses might have 
further contributed to this clinically unusual non-progressive profile. Although these are naturally occurring 
cases, and not the result of a clinical intervention, they provide knowledge on how to achieve a functional cure for 
HIV-1 infection. Based on all these evidencies we believe that these individuals do not require any ART. Perhaps 
other individuals, most probably within the persistent EC, LTNP-EC, and EEC groups with similar host (at least 
three to four alleles), inmune responses (with a polyfunctionality index > 0.50) and viral factors (with stable viral 
diversity (below 0.010 ± 0.003 (s/n) throughout the entire follow-up) could also have spontaneously achieved a 
HIV-1 functional cure51.
Four previous cases of durable control over HIV replication without ART have been reported12. While those 
cases also had extraordinarily low HIV burdens, they differed from ours in their shorter follow up (median of 
9 years since HIV diagnosis) and their weak reactive Western blots. A more recent study in HIV-1 Controllers 
(HIC) followed up for a median of 21 years has shown a similar small HIV blood reservoir in the presence of weak 
T-cell activation levels11. Our study adds three new additional characteristics to this EEC phenotype: (i) even 
more time since HIV diagnosis without ART, (ii) low viral diversity and lack of viral evolution over the years, and 
(iii) inflammatory markers in peripheral blood similar to those in healthy donors.
The incidental accumulation of protective host factors, unfit and/or defective viruses that precluded viral evo-
lution and diversification, effective innate and adaptive immune responses, might have take place simultaneously 
to achieve a HIV-1 functional spontaneous cure. This model of control suggests that new curative strategies would 
be successful combining approaches that achieve a reduction of the HIV-1 latent reservoirs, maintain extremely 
low viral diversity, an impaired viral fitness, and enhanced HIV-1 specific immune responses.
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